Riga-Fede disease: A systematic review and report of two cases.

AIM: The term Riga-Fede disease has been used historically to describe traumatic ulceration that occurs on the ventral surface of tongue, buccal mucosa, gum or floor of the tongue in newborns and infants. It is most often associated with natal and neonatal teeth in newborns. The painful symptoms may be absent or acute, up to the point of preventing the baby from feeding. The aim of this work is to offer a description of the therapeutic solutions for the treatment of this pathological condition, with a review of the literature and the report of two cases. MATERIALS: A systematic review of the literature of articles presenting Riga-Fede Disease associated with natal and neonatal teeth was performed following the PRISMA protocol (Prefered Reporting Items for Systematic Reviews and Meta-Analyses). This bibliographic search was performed through two databases, PubMed and Google Scholar. CONCLUSION: Extraction and ameloplasty are the most effective treatments in the resolution of the Riga-Fede disease associated with natal/neonatal teeth. In the case of high dental mobility, resulting in an increased risk of exfoliation and possible tooth ingestion/inhalation, extraction is the therapeutic treatment of choice. When nutrition is not compromised, ameloplasty is the treatment of choice, as it is less invasive and more conservative.

A comparison of nimesulide beta cyclodextrin and nimesulide in postoperative dental pain.

The aim of this study was to assess the efficacy and tolerability of single doses of nimesulide beta cyclodextrin compared with nimesulide in patients with dental pain following surgical procedures. This was a randomised, double-blind, between-patient, multicentre study involving 148 outpatients suffering from moderate to severe pain, who received single doses of either 400 mg nimesulide beta cyclodextrin or 100 mg nimesulide. The principal criterion for efficacy was pain intensity assessed on a visual analogue scale (VAS) 15 minutes after drug intake. Pain intensity was further evaluated 30, 45, 90, 120, 180, 240 and 360 minutes after dosing. Pain relief was evaluated at the same time points by means of a categorical scale. The time point of first pain relief, the use of rescue medication and the global evaluation of efficacy were also recorded. The reduction in pain intensity was significantly more pronounced in the nimesulide beta cyclodextrin group at 15, 30, 45 and 60 minutes (p < 0.01). Pain relief was significantly greater (p < 0.05) and more rapid with nimesulide beta cyclodextrin. In the patient overall assessment of efficacy, nimesulide beta cyclodextrin and nimesulide were rated excellent or good by 95% and 92% respectively; only one patient in the nimesulide beta cyclodextrin group needed rescue medication. Both study drugs were effective and well tolerated in the treatment of acute dental pain, with nimesulide beta cyclodextrin showing a faster onset of analgesic action.